A British study found that virtual chromoendoscopy has a higher neoplasia detection rate than other endoscopic modalities ...
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...
For more than a decade, Michelle Hobson endured extreme fatigue, excruciating abdominal pain, and repeated hospital visits.
Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.
Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...
12d
Medpage Today on MSNStudies Point to Several Options for Ulcerative Colitis After Anti-TNF FailureSAN FRANCISCO -- Research presented at the annual Crohn's and Colitis Congress included studies comparing the effectiveness ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
Data presented at key congresses in North America and EuropeCAMBRIDGE, United Kingdom, Feb. 21, 2025 (GLOBE NEWSWIRE) -- ...
13d
Onlymyhealth on MSNBloating Is Common In People With Ulcerative Colitis: Expert Explains Its Causes And Management TipsUlcerative Colitis UC is a chronic inflammatory bowel disease that can lead to frequent bloating Read on to learn its causes ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results